Plain-English translation of NCT07392229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The MAZINGA study is testing whether zanubrutinib, a newer type of immune-targeting medication, can help people with anti-MAG neuropathy—a rare condition where the body's immune system mistakenly damages the protective coating around nerves. Researchers want to see if this medication can improve nerve function and reduce nerve damage symptoms over one year of treatment.
Anti-MAG neuropathy is a rare immune disorder that currently has limited treatment options, and existing treatments don't work well for everyone. This trial is exploring whether this medication, which works differently than older treatments, might offer patients a better chance at improving their nerve function and quality of life.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth daily for 12 months while visiting the clinic regularly for check-ups. During these visits, doctors will perform nerve tests, blood work, and physical exams to see how the medication is affecting your nerve function and overall health. The study follows participants for up to 4 years total to monitor long-term effects and recovery.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Italy